| 1. |
- Green, Henrik, et al.
(författare)
-
CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity
- 2010
-
Ingår i: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. - : Springer Science and Business Media LLC. - 0031-6970 .- 1432-1041. ; 66:4, s. 383-386
-
Tidskriftsartikel (refereegranskat)abstract
- Imatinib is currently used for the treatment of chronic myeloid leukemia (CML). The main metabolite CGP74588 has similar potency to that of imatinib and is a product of CYP3A4 and CYP3A5 metabolism. However, the clinical significance of the metabolism on therapeutic response and pharmacokinetics is still unclear. We designed this study to investigate the role of the CYP3A activity in the response to imatinib therapy. Fourteen CML patients were phenotyped for in vivo CYP3A activity using quinine as a probe drug. The plasma concentration ratio of quinine and its CYP3A metabolite was used for assessing CYP3A activity. The patients were divided into complete molecular responders with undetectable levels of BCR-ABL transcripts after 12 months of therapy and into partial molecular responders who had failed to achieve a complete molecular response. Patients that achieved complete molecular response showed significantly (Mann-Whitney U-test, p = 0.013) higher in vivo CYP3A activity (median quinine metabolic ratio = 10.1) than patients achieving partial molecular response (median = 15.9). These results indicate a clinical significance of the CYP3A activity and its metabolic products in CML patients treated with imatinib.
|
|
| 2. |
|
|
| 3. |
- Kihlberg, Johan, 1970-, et al.
(författare)
-
Ackumulering av överskottsjärn kan bestämmas med MR
- 2009
-
Ingår i: Ackumulering av överskottsjärn kan bestämmas med MR.
-
Konferensbidrag (refereegranskat)abstract
- Järnöverskott kan vara toxiskt i kroppen. Järnöverskott ses fr a efter multipla blodtransfusioner vid vissa blodsjukdomar. Internationellt är den vanligaste orsaken thalassemi. Antalet patienter med denna problematik är i Sverige ännu begränsat. Järnöverskott kan leda till allvarlig, svårbehandlad hjärtsvikt man kan behandlas med chelaterande perorala läkemedel och styrs då i allmänhet utifrån ferritin/s. Vår hypotes var att överensstämmelsen mellan järnöverskott och transferrin är låg, att järnöverskott bättre karaktäriseras med MR som också kan differentiera mellan järnöverskott i hjärta respektive lever.
|
|
| 4. |
- Norin, Stefan, et al.
(författare)
-
Severe infusion-related reactions are uncommon in rituximab-treated CLL patients in clinical practice: Results from a Swedish national observational study
- 2015
-
Ingår i: Leukemia Research. - : Elsevier. - 0145-2126 .- 1873-5835. ; 39:1, s. 33-37
-
Tidskriftsartikel (refereegranskat)abstract
- There have been concerns about serious infusion-related adverse drug reactions (ADR) with rituximabin chronic lymphocytic leukemia (CLL). We therefore conducted an observational trial in which CLL patients planned for rituximab-containing therapy were eligible. Ninety-six patients from 19 centers were enrolled. The most common regimen was rituximab, fludarabine and cyclophosphamide. Fifty-six patients experienced ADR during rituximab infusion. Reactions greater than= grade 3 occurred in five patients and no cases of tumor lysis syndrome were recorded. Despite a high number of circulating tumor cells few severe ADR were noted. Thus, rituximab containing regimens can be considered safe for CLL patients in general practice.
|
|
